Sherbrooke Park Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,524	Closed	-$125K	–	224
2025 Q3	$125K	Buy	16,524 +3,866	+31%	+$32.2K	0.06%	432
2025 Q2	$113K	Buy	+12,658	New	+$118K	0.05%	450
2025 Q1	–	Sell	-34,628	Closed	-$260K	–	619
2024 Q4	$260K	Buy	34,628 +7,134	+26%	+$54.2K	0.08%	467
2024 Q3	$209K	Buy	+27,494	New	+$209K	0.05%	736
2024 Q2	–	Sell	-78,814	Closed	-$400K	–	913
2024 Q1	$400K	Buy	78,814 +66,051	+518%	+$371K	0.08%	443
2023 Q4	$76.5K	Buy	+12,763	New	+$74K	0.04%	419

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sherbrooke Park Advisers's BCRX Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 16,524 shares — an estimated $125K sold.

Sherbrooke Park Advisers first reported a position in BCRX in Q4 2023 and held it in 6 quarters. The position peaked at $400K in Q1 2024. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Sherbrooke Park Advisers reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 16,524 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $125K.
Sherbrooke Park Advisers first reported a position in BioCryst Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Sherbrooke Park Advisers's BioCryst Pharmaceuticals position peaked at $400K in Q1 2024.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.